Author

N. Stransky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1

Frequent Co-Authors

R. Kulicke· 2 shared A. Filer· 1 shared A. Garner· 1 shared A. H. Yeaton· 1 shared A. Herrera· 1 shared A. J. Bhutkar· 1 shared A. Jainarayanan· 1 shared A. Jonsson· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. Kulicke

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth

A. Rashidfarrokhi, R. Pillai, Y. Hao, W. Wu, B. Karadal-Ferrena, S. G. dimitriadoy, M. Cross, A. H. Yeaton, S. Ming Huang, A. J. Bhutkar, A. Herrera, S. Rajalingam, M. Hayashi, K.-l. Huang, E. Bartnicki, , T. Papagiannakopoulos

This study identifies a LKB1-LIF signaling axis in tumors that promotes immune evasion by reprogramming myeloid cells, and shows that inhibiting LIF signaling reduces tumor growth.

bioRxiv · Jul 15, 2023 · PreprintCancer Biology

A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

T. Thomas, C. Rich-Griffin, M. Pohin, M. Friedrich, D. Aschenbrenner, J. Pakpoor, A. Jainarayanan, A.-I. Voda, R. Sanches Peres, E. Nee, D. Sathananthan, D. Kotliar, J. Turner, S. Nayar, F. Zhang, , C. Buckley

This study creates a therapeutic atlas of anti-TNF treatment in IBD, showing disease- and therapy-specific cellular changes and identifying IFN signalling as a potential target for JAK inhibition.

bioRxiv · May 5, 2023Immunology

Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma

S. S. Schalm, E. O'Hearn, K. Wilson, T. P. LaBranch, G. Silva, Z. Zhang, L. DiPietro, N. Bifulco, R. Woessner, N. Stransky, D. Sappal, R. Campbell, R. Lobbardi, M. Palmer, J. Kim, , K. P. Hoeflich

This study evaluates PRKACA as a therapeutic target for fibrolamellar carcinoma using PDX models and shows that its knockdown or inhibition reduces tumor growth.

bioRxiv · Jan 31, 2022 · PreprintCancer Biology